Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 6/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | RHOA | P61586 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 5/20 | 0.38 |
| ▸ | JAK1 | P23458 | 5/20 | 0.38 |
| ▸ | TYK2 | P29597 | 5/20 | 0.38 |
| ▸ | JAK3 | P52333 | 5/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL4358813 | 0.96 | ALK (0.46) | ALKKMT2ASMN1; SMN2TSHRRHOA | |
| SCHEMBL1075119 | 0.96 | ALK (0.51) | ALKKMT2ASMN1; SMN2TSHRJAK2 | |
| Trifluoroacetic Acid SCHEMBL4358083 | 0.92 | ALK (0.47) | ALKKMT2ASMN1; SMN2JAK2JAK1 | |
| SCHEMBL1075366 | 0.92 | ALK (0.52) | ALKJAK2JAK1TYK2JAK3 | |
| SCHEMBL1075923 | 0.91 | ALK (0.50) | ALKSMN1; SMN2RHOAJAK2JAK1 | |
| SCHEMBL4363395 | 0.90 | ALK (0.49) | ALKJAK2JAK1TYK2JAK3 | |
| SCHEMBL4364967 | 0.90 | ALK (0.51) | ALKSMN1; SMN2JAK2JAK1TYK2 | |
| SCHEMBL4362936 | 0.90 | ALK (0.54) | ALKJAK2JAK1TYK2JAK3 | |
| SCHEMBL4358516 | 0.89 | ALK (0.48) | ALKJAK2JAK1TYK2JAK3 | |
| SCHEMBL4360802 | 0.89 | ALK (0.48) | ALKJAK2JAK1TYK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8871753-B2 | Macrocyclic compounds and their use as kinase inhibitors | INCYTE CORPORATION (US) | 2014-10-28 | — | — | US | claimed |
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-11-19 | — | — | US | claimed |
| US-8871753-B2 | Macrocyclic compounds and their use as kinase inhibitors | INCYTE CORPORATION (US) | 2014-10-28 | — | — | US | disclosed |
| US-8871753-B2 | Macrocyclic compounds and their use as kinase inhibitors | INCYTE CORPORATION (US) | 2014-10-28 | — | — | US | disclosed |
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-11-19 | — | — | US | disclosed |
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | JAK2, JAK1, ALK | ALK 3/4885KMT2A 382/4885SMN1; SMN2 4274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.